Genomic cancer medicine promises revolutionary change in oncology. The
impacts of ‘personalized medicine’, based upon a molecular
classification of cancer and linked to targeted therapies, will extend
from individual patient outcomes to the health economy at large. To
address the ‘whole-of-system’ impact of genomic cancer medicine, we have
established a prospective cohort of patients with newly diagnosed
cancer in the state of Victoria, Australia, about whom we have collected
a broad range of clinical, demographic, molecular, and patient-reported
data, as well as data on health resource utilization. Our goal is to
create a model for investigating public investment in genomic medicine
that maximizes the cost:benefit ratio for the Australian community at
large.
Read More
Read More
No comments:
Post a Comment